Prescription Required
Glyxambi 25mg/5mg Tablet 10s is a combination medicine that helps control blood sugar levels.
It is unsafe to consume alcohol with Glyxambi 25mg/5mg Tablet 10s.
Glyxambi 25mg/5mg Tablet 10s may be unsafe to use during pregnancy. Animal studies conducted so far have shown harmful effects of medicine on developing baby while limited human studies have conducted. Before prescribing it; doctor will weigh the potential risks and benefits associated with it.
Glyxambi 25mg/5mg Tablet 10s is probably unsafe to use during breastfeeding. Human studies conducted revealed that the drug can pass through the breastmilk and can harm the baby.
It is not known whether Glyxambi 25mg/5mg Tablet 10s alters the ability to drive. Avoid driving if you experience symtpoms that impact driving ability.
Glyxambi 25mg/5mg Tablet 10s should be used with caution in patients with kidney disease. Dose adjustment for the medicine may be required. Please consult your doctor. Use of Glyxambi 25mg/5mg Tablet 10s is contraindicated in patients with severe kidney disease or in dialysis.
Glyxambi 25mg/5mg Tablet 10s is safe to use in patients with liver disease. No dose adjustment of Glyxambi 25mg/5mg Tablet 10s is recommended. However, avoid the use if having severe hepatic impairment.
Glyxambi 25mg/5mg Tablet 10s is a combination of two antidiabetic medicines: Empagliflozin and Linagliptin. Empagliflozin acts by eliminating excess glucose from the body through urine. Linagliptin works by lowering glucose production in the liver, delaying glucose absorption from the intestines, and increasing the body's sensitivity to insulin.
Take the missed dose when you remember. If the next dose is approaching, skip the missed one. Avoid doubling up to compensate for a missed dose.
Diabetes Mellitus type 2 - Either the body stops producing enough insulin, or there is resistance to insulin action.
Content Updated on
Friday, 17 May, 2024Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA